These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 24910427)

  • 1. Long-term health of dopaminergic neuron transplants in Parkinson's disease patients.
    Hallett PJ; Cooper O; Sadi D; Robertson H; Mendez I; Isacson O
    Cell Rep; 2014 Jun; 7(6):1755-61. PubMed ID: 24910427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extracellular α-synuclein enters dopaminergic cells by modulating flotillin-1-assisted dopamine transporter endocytosis.
    Kobayashi J; Hasegawa T; Sugeno N; Yoshida S; Akiyama T; Fujimori K; Hatakeyama H; Miki Y; Tomiyama A; Kawata Y; Fukuda M; Kawahata I; Yamakuni T; Ezura M; Kikuchi A; Baba T; Takeda A; Kanzaki M; Wakabayashi K; Okano H; Aoki M
    FASEB J; 2019 Sep; 33(9):10240-10256. PubMed ID: 31211923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct dopaminergic abnormalities in traumatic brain injury and Parkinson's disease.
    Jenkins PO; Roussakis AA; De Simoni S; Bourke N; Fleminger J; Cole J; Piccini P; Sharp D
    J Neurol Neurosurg Psychiatry; 2020 Jun; 91(6):631-637. PubMed ID: 32381639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional Rescue of Dopaminergic Neuron Loss in Parkinson's Disease Mice After Transplantation of Hematopoietic Stem and Progenitor Cells.
    Altarche-Xifro W; di Vicino U; Muñoz-Martin MI; Bortolozzi A; Bové J; Vila M; Cosma MP
    EBioMedicine; 2016 Jun; 8():83-95. PubMed ID: 27428421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation in RGS6-deficient mice.
    Luo Z; Ahlers-Dannen KE; Spicer MM; Yang J; Alberico S; Stevens HE; Narayanan NS; Fisher RA
    JCI Insight; 2019 May; 5(13):. PubMed ID: 31120439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson's disease.
    Hallett PJ; Deleidi M; Astradsson A; Smith GA; Cooper O; Osborn TM; Sundberg M; Moore MA; Perez-Torres E; Brownell AL; Schumacher JM; Spealman RD; Isacson O
    Cell Stem Cell; 2015 Mar; 16(3):269-74. PubMed ID: 25732245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine compartmentalization, selective dopaminergic vulnerabilities in Parkinson's disease and therapeutic opportunities.
    Uhl GR
    Ann Clin Transl Neurol; 2019 Feb; 6(2):406-415. PubMed ID: 30847375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The bioengineering of stem cells to create dopamine replacement neurons is not the solution for Parkinson's.
    Carey RJ; Carey JL
    Pharmacol Biochem Behav; 2017 Dec; 163():36-37. PubMed ID: 29066358
    [No Abstract]   [Full Text] [Related]  

  • 9. Variability in neuronal expression of dopamine receptors and transporters in the substantia nigra.
    Reyes S; Cottam V; Kirik D; Double KL; Halliday GM
    Mov Disord; 2013 Sep; 28(10):1351-9. PubMed ID: 23674405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repulsive Guidance Molecule a (RGMa) Induces Neuropathological and Behavioral Changes That Closely Resemble Parkinson's Disease.
    Korecka JA; Moloney EB; Eggers R; Hobo B; Scheffer S; Ras-Verloop N; Pasterkamp RJ; Swaab DF; Smit AB; van Kesteren RE; Bossers K; Verhaagen J
    J Neurosci; 2017 Sep; 37(39):9361-9379. PubMed ID: 28842419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic reduction of mitochondrial complex I function does not lead to loss of dopamine neurons in vivo.
    Kim HW; Choi WS; Sorscher N; Park HJ; Tronche F; Palmiter RD; Xia Z
    Neurobiol Aging; 2015 Sep; 36(9):2617-27. PubMed ID: 26070241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of α-synuclein pathology on transplanted hESC-derived dopaminergic neurons in a humanized α-synuclein rat model of PD.
    Hoban DB; Shrigley S; Mattsson B; Breger LS; Jarl U; Cardoso T; Nelander Wahlestedt J; Luk KC; Björklund A; Parmar M
    Proc Natl Acad Sci U S A; 2020 Jun; 117(26):15209-15220. PubMed ID: 32541058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
    Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cryopreservation Maintains Functionality of Human iPSC Dopamine Neurons and Rescues Parkinsonian Phenotypes In Vivo.
    Wakeman DR; Hiller BM; Marmion DJ; McMahon CW; Corbett GT; Mangan KP; Ma J; Little LE; Xie Z; Perez-Rosello T; Guzman JN; Surmeier DJ; Kordower JH
    Stem Cell Reports; 2017 Jul; 9(1):149-161. PubMed ID: 28579395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
    Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
    Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell-specific overexpression of COMT in dopaminergic neurons of Parkinson's disease.
    Kuzumaki N; Suda Y; Iwasawa C; Narita M; Sone T; Watanabe M; Maekawa A; Matsumoto T; Akamatsu W; Igarashi K; Tamura H; Takeshima H; Tawfik VL; Ushijima T; Hattori N; Okano H; Narita M
    Brain; 2019 Jun; 142(6):1675-1689. PubMed ID: 31135049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent Advances in the Development of Stem-Cell-Derived Dopaminergic Neuronal Transplant Therapies for Parkinson's Disease.
    Barbuti PA; Barker RA; Brundin P; Przedborski S; Papa SM; Kalia LV; Mochizuki H;
    Mov Disord; 2021 Aug; 36(8):1772-1780. PubMed ID: 33963552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of Parkinson's disease pathophysiology for the development of cell replacement strategies and drug discovery in neurodegenerative diseases.
    Pan-Montojo F; Funk RH
    CNS Neurol Disord Drug Targets; 2012 Nov; 11(7):907-20. PubMed ID: 23131153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson's disease: Involvement of mitochondrial dysfunctions and oxidative stress.
    Paul R; Choudhury A; Kumar S; Giri A; Sandhir R; Borah A
    PLoS One; 2017; 12(2):e0171285. PubMed ID: 28170429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts.
    Politis M; Wu K; Loane C; Quinn NP; Brooks DJ; Oertel WH; Björklund A; Lindvall O; Piccini P
    Sci Transl Med; 2012 Apr; 4(128):128ra41. PubMed ID: 22491951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.